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The Ripple Effect of Genomics
 Technology has been the the primary 
driver of Genomics Advances.
 Haemophilus influenzae (1995)
 Fifteen years later we are seeing evidence 
of data generation capabilities providing a 
feedback loop driving novel technology 
development.
J. Craig Venter
Visionary leader of 
the JCVI. 
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Sequence Generation Throughput: 
An Ever Moving Target
454 FLX 800 2,000,000
Illumina GA Iix 5,000 50,000,000
SOLiD 3 plus 3,000 60,000,000
Seg1 (PB2)
Seg2 (PB1)
Seg3 (PA)
1
2
3
8
NCBI
Collections
RNA preparation
Primer
Design
160 virus genomes/month
Seg4 (HA)
Seg5 (NP)
Seg6 (NA)
Seg7 (M)
Seg8 (NS)
4
57
6
Closure
Assembly
Tracking
Validation
RT-PCR
Sequencing
JCVI Rapid Response to The Swine-Origin Influenza Pandemic
Genetic relatedness of all sequenced HRV isolates
• HRV sequences cluster into 
three, perhaps four distinct 
groups or clades
• Clade “C” is a rapidly emerging 
cause of flu-like illness and is 
undersampled
• Recombination plays a 
significant role, previously 
unrecognized, in the evolution of 
new rhinovirus species
• High rate of viral evolution may 
lead to rapid drug resistance
• Species specific hypervariable 
region in 5’ UTR may provide 
differing pathogenic potential to 
individual rhinovirus species 
(analogous to poliovirus 
mechanism)
• A new starting point for 
investigating HRV epidemiology
GOS dataset is expanding the protein universe
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How Can We Functionally Mine 
Genomic Data?
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Source: Genbank Release Notes 176.0
ftp://ftp.ncbi.nih.gov/genbank/gbrel.txt
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Atrazine Bioremediation
Open Questions
How many genes
are encoded by life
on our planet?
Is there a gene
for every natural 
organic compound?
Lawrence Wackett, U. Minn
Human Insulin: 1st Drug Produced in 
Bacteria
Synthetic genomics is a new field that 
engages in the design and assembly of genes 
and chromosomes from chemically 
synthesized oligonucleotides to create cells 
with properties unobtainable by conventional 
molecular biology methods.
Cells as machines, biological functions in 
parts boxes of interchangeable parts. (MIT 
researcher Drew Endy’s Registry of Standard 
Biological Parts http://parts.mit.edu/)
The Potential of Synthetic Genomics
From reading to writing the genome code
…and synthesizing cells that make useful products
T
A
G C
DNA Synthesizer
Completely assembled
Synthetic Chromosome
Pharmaceuticals
Substitutes for 
Petrochemicals
Bio-Energy
Sunlight
Plant Biomass
CO2
“Chew-back Anneal”
5.4kb 6.6kb 5.3kb 5.8kb
300bp overlaps
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6.0kb 5.4kb 6.5kb 6.5kb
Eight Cassettes Assemble Efficiently
Chew-back Time (min):
2 4 6 10 128 14 16 180
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Rapid gene synthesis 
from oligonucleotides

24kb 72kb 144kb 290kb 580kb
1 2 3 4
6kb
Assembly of 101 Synthetic Gene Cassettes
1/25 1/8 1/4 1/2 Whole
etc.

Construction of a synthetic M. genitalium genome in yeast
Gibson D G et al. PNAS 2008;105:20404-20409
©2008 by National Academy of Sciences
One Model for Transplantation of tetR M. 
capricolum Donor Genomes into Recipient M. 
mycoides Cells
Cell growth and Division Leads to Daughter Cells 
Containing Different Genomes

Intractable Organisms Redesigned
 Cyanobacteria do much of 
the photosynthesis on 
earth. Unfortunately, they 
are hard to work with. 
 Can we clone their 
genomes into yeast and 
use yeast genetics to 
manipulate  cyanobacterial 
metabolism to convert 
sunlight, water and CO2
into fuels? 
Can Eukaryotic Algae Be 
Re-engineered?
 Chloroplasts and mitochondria 
were once endosymbions
 Can we design new 
organelles with broader 
ranges of photoreceptor 
molecules?
 Oils comprise 70% of the 
mass of some slow growing 
algae, can we engineer them 
to grow rapidly
Design Codon Opt. Oligo Synthesis
Synthetic Designer v1.0
JCVI Policy Center
• Along with the promise of 
benefits, all new 
technologies raise societal 
concerns
• Five key societal concerns:
 Bioterrorism
 Laboratory Safety
 Harm to the Environment
 Distribution of Benefits
 Ethical and Religious
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Artemisinin
Antimalarial drug extracted 
from wormwood bark now 
synthesized by engineering a 
20 gene synthetic pathway 
into yeast then tuning 
expression of each gene
“Production of the antimalarial drug precursor artemisinic acid in engineered yeast “ 
ZJ.D. Keasling et al. Nature 440, 940-943 (13 April 2006) 
Reverse Vaccinology:  From Genome 
Sequence to Vaccine Candidates
Why It is Hard To Develop Vaccines: 
Diversity
Nature Medicine 10, S77 - S81 (2004)
Pathogen diversity and 
dynamics = a variable and 
moving target
But also the process is 
fundamentally flawed; depends on 
using mice, then primates before 
humans.  We have an idea.  From 
target ID to human validation using 
an artificial human immune system
CCUGAGCCA
ACUAUUGAU
Pathogen            ORF Clone                                              Protein
Transfer
media to 
disease model
VS LTE Disease Model
epithelium
The Human Genome
This Milestone was 
compared by some to 
sending man to the moon!
PLoS Biology 2007 5:e254
Published Genome-Wide Associations through 12/2009, 
658 published GWA at p<5x10-8
NHGRI GWA Catalog
www.genome.gov/GWAStudies





Infusion of Funding for Personalized Medicine
Personal Genome Project
Mission: To sequence the genomes of 100,000
Human volunteers.
Targeted Sequencing 
Template
Amplification
Up to 1.5 million 
independent PCR 
reactions per run
Merge
Sequencing
Diversity of the microbiome on the human body
Mouth
Esophagus
Colon
Stomach
Skin
Massive Bacterial Diversity
Bacteria that killed Virginia teen found in other 
schools
(October 18, 2007)
•17-year-old student died of drug-resistant strain of bacteria on Monday
•Methicillin-resistant Staphylococcus aureus, MRSA, blamed for his death
•MRSA cases also reported in Connecticut, Maryland, Ohio, Michigan
•MRSA killed more people than HIV/AIDS in 2005, new study finds
http://www.cnn.com/2007/HEALTH/10/18/mrsa.cases/index.html
MRSA 'superbug' found in ocean, public beaches
(September 12, 2009)
http://www.usatoday.com/news/health/2009-09-12-staph-superbug-MRSA-beaches_N.htm
Induction of Error-prone Polymerases
Wild type lexA Mutant
30 minute incubation
Determine which genes are
activated when treated with 
antibiotics after 30 min
Treat with Antibiotic
Determine which genes are
activated when treated with 
antibiotics after 2 hours
B. anthracis
P. aeruginosa
S. aureus
Collect cells, extract RNA 
and make probes
2 hour incubation
Collect cells, extract RNA 
and make probes
Centrifugation
Load Enzyme 
Beads
Whole Genome Re-sequencing
to Identify Causative SNPs
Load beads into 
PicoTiter™Plate 
Centrifugation
HT DNA sequencing may now be used to 
re-sequence 1000’s of genomes selected for 
resistance to a number of anti-microbials. 
Identified mutations generate new diagnostic 
potential but also define novel drug targets.
Conclusions
 Genomics is advancing rapidly and in many 
more directions than could have been imagined 
even 10 years ago.
 Genomics holds enormous promise to 
improve human health.
 Genomics, initially driven by a single 
technology is now invigorating a wide array of 
technologies and small businesses.
 Genomics raises serious concerns requiring
policy and law makers to weigh the benefits and 
risks associated with our new capabilities.
